Publication | Open Access
Targeting Podoplanin for the Treatment of Osteosarcoma
28
Citations
27
References
2022
Year
Targeting PDPN with a neutralizing antibody against PDPN-CLEC-2 without antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity is a novel therapeutic strategy for PDPN-positive osteosarcoma.
| Year | Citations | |
|---|---|---|
Page 1
Page 1